Prestige Biopharma secures 2022 Asia-Pacific Bioprocessing Excellence Awards

KUALA LUMPUR, April 1 (Bernama) -- Prestige Biopharma Limited, a Singapore-based leading biopharmaceutical with operations in USA and South Korea, has announced its recognition as the grand winner of the Bioprocessing Excellence in SEA (South-East Asia).

The Awards Ceremony was held in conjunction with the 9th Biologics Manufacturing Asia and 6th Biologistics World Asia 2022 hybrid Conference, which was streamed live on March 29 - 30, 2022.

Asia Pacific Bioprocessing Excellence Awards recognises exceptional bioprocessing experts, organisations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality.

According to a statement, the panel of expert judges includes key opinion leaders with more than 20 years of experience from all the key players in Asia and globally.

“We are very proud to receive this award and thank you for recognising Prestige’s passion for driving innovation and change in bioprocessing,” said Dr Deborah Moshinsky, Head of Global R&D of Prestige in her acceptance speech.

“Prestige Group has undergone a significant expansion to our manufacturing capabilities. Our EU-GMP certified facility with global compliance recognition is currently expanding its capacity up to 234,000 litres through its 2nd Campus developments.”

Prestige has developed biosimilars and first-in-class antibody drugs of high quality and strong cost competitiveness in expedited development programmes, with its proprietary bioprocessing technology.

Prestige’s leading pipeline HD201 trastuzumab (Tuzune®) is currently under EU EMA’s MAA review and its manufacturing facility, Prestige Biologics, received European Union Good Manufacturing Practices (GMP) certification last February.

More details at www.prestigebiopharma.com.

-- BERNAMA